SAMHSA: COVID-19 Public Health Emergency Response and 42 CFR Part 2 GuidanceMarch 19, 2020
The Substance Abuse and Mental Health Services Administration (SAMHSA) is providing guidance to ensure that SUD treatment services are uninterrupted during the COVID-19 public health emergency.
Webinar: MOUD and the COVID-19 National Emergency ResponseMarch 19, 2020
Join Dr. Hannah Snyder, Jodi Manz, MSW, and Daniel McClughen, Esq. as they review key steps, fast evolving regulatory changes, and newly issued guidance around MOUD during the COVID-19 pandemic.
Recorded Webinar | Slides | Q&A
SAMHSA: FAQ on the provision of methadone and buprenorphine for the treatment of OUD in the COVID-19 EmergencyMarch 19, 2020
The Substance Abuse and Mental Health Services Administration (SAMHSA) has compiled an FAQ on prescribing MOUD during the COVID-19 pandemic.
SAMHSA: Opioid Treatment Program (OTP) GuidanceMarch 17, 2020
The Substance Abuse and Mental Health Services Administration (SAMHSA) expands previous guidance to provide increased flexibility during the COVID-19 pandemic and affirms its commitment to supporting OTPs in any way possible during this time.
DEA: Expanded MOUD Telemedicine GuidanceMarch 17, 2020
The Drug Enforcement Administration (DEA) has provided further guidance on the expanded use of telemedicine for medications for opioid use disorder (MOUD) services during the COVID-19 national emergency.
HHS/OCR: Enforcement Discretion for Telehealth Remote Communications During COVID-19March 17, 2020
The Office for Civil Rights (OCR) will exercise enforcement discretion and will waive potential penalties for HIPAA violations against health care providers that serve patients through everyday communications technologies during the COVID-19 emergency.